Triple-negative breast cancers (TNBCs) are a heterogenous group of breast cancers characterized by poor prognosis because they are not amenable to targeted therapies. We have taken into account that altered expression of Raf-1 kinase inhibitor protein (RKIP), a tumor and metastasis suppressor and a promoter of drug-induced apoptosis, is frequent in TNBCs and may be involved in their aggressive biology. Interestingly, the analysis of the possible mechanisms of RKIP downregulation in TNBCs permits the identification and recapitulation of different possible approaches, including epigenetic modulation, e.g., by DNA demethylating agents or histone deacetylase inhibition, and NF-κB inhibition. These approaches are currently of great interest in the field of TNBC therapy.
D'Alessandro, N., Poma, P., Labbozzetta, M., Vivona, N., NOTARBARTOLO DI VILLAROSA, M. (2014). Mechanisms of Raf-1 Kinase Inhibitor Protein Dysregulation in Triple-Negative Breast Cancers and Identification of Possible Novel Therapeutic Approaches for These Tumors. FORUM ON IMMUNOPATHOLOGICAL DISEASES AND THERAPEUTICS, 5(3-4), 215-222 [10.1615/ForumImmunDisTher.2015013936].
Mechanisms of Raf-1 Kinase Inhibitor Protein Dysregulation in Triple-Negative Breast Cancers and Identification of Possible Novel Therapeutic Approaches for These Tumors
D'ALESSANDRO, Natale;POMA, Paola;LABBOZZETTA, Manuela;VIVONA, Nicoletta;NOTARBARTOLO DI VILLAROSA, Monica
2014-01-01
Abstract
Triple-negative breast cancers (TNBCs) are a heterogenous group of breast cancers characterized by poor prognosis because they are not amenable to targeted therapies. We have taken into account that altered expression of Raf-1 kinase inhibitor protein (RKIP), a tumor and metastasis suppressor and a promoter of drug-induced apoptosis, is frequent in TNBCs and may be involved in their aggressive biology. Interestingly, the analysis of the possible mechanisms of RKIP downregulation in TNBCs permits the identification and recapitulation of different possible approaches, including epigenetic modulation, e.g., by DNA demethylating agents or histone deacetylase inhibition, and NF-κB inhibition. These approaches are currently of great interest in the field of TNBC therapy.File | Dimensione | Formato | |
---|---|---|---|
FIDT13936_final.pdf
Solo gestori archvio
Descrizione: articolo principale
Dimensione
612.58 kB
Formato
Adobe PDF
|
612.58 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.